Novartis Ag (NVS) Income from Continuing Operations (2009 - 2026)

Novartis Ag has disclosed Income from Continuing Operations across 18 years of filings, most recently posting $5.3 billion for Q2 2026.

• In Q2 2026, Income from Continuing Operations rose 4.82% year-over-year to $5.3 billion; the TTM figure through Jun 2026 stood at $24.5 billion (down 3.58% YoY), while the FY2025 annual figure was $18.7 billion, up 22.14% from the prior year.
• Income from Continuing Operations came in at $5.3 billion for Q2 2026 at Novartis Ag, up from $4.5 billion in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of $11.6 billion in Q4 2024 to a low of $1.6 billion in Q3 2023.
• Average Income from Continuing Operations over 5 years is $4.8 billion, with a median of $4.4 billion recorded in 2024.
• Year-over-year, Income from Continuing Operations slumped 63.89% in 2022 and surged 125.33% in 2024.
• Over 5 years, Income from Continuing Operations stood at $6.5 billion in 2022, then advanced by 16.6% to $7.6 billion in 2023, then soared by 53.36% to $11.6 billion in 2024, then decreased by 11.63% to $10.2 billion in 2025, then tumbled by 48.44% to $5.3 billion in 2026.
• Per Business Quant data, the three most recent Income from Continuing Operations figures were $5.3 billion in Q2 2026, $4.5 billion in Q1 2026, and $10.2 billion in Q4 2025.